Anest. intenziv. Med. 2026;37(1):45-46 | DOI: 10.36290/aim.2026.002

A new consensus framework for understanding immune dysregulation in sepsis and critical illnessShort Communication

Karvunidis T.1, 2
1 Jednotka intenzivní péče, I. interní klinika, Fakultní nemocnice Plzeň
2 Lékařská fakulta a Biomedicínské centrum v Plzni, Univerzita Karlova

A Nature Medicine publication redefines the biology of critically ill patients and opens the way to precisely targeted immunotherapy for sepsis and selected critical illnesses.

Received: January 9, 2026; Revised: January 14, 2026; Accepted: January 14, 2026; Prepublished online: March 9, 2026; Published: April 9, 2026  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Karvunidis T. A new consensus framework for understanding immune dysregulation in sepsis and critical illness. Anest. intenziv. Med. 2026;37(1):45-46. doi: 10.36290/aim.2026.002.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Purchase PDF - 40 CZK (1.7 EUR)
    will be unlocked 9.4.2027

    References

    1. Moore AR, Zheng H, Ganesan A, Hasin­‑Brumshtein Y, Maddali MV, Levitt JE, et al. A consensus immune dysregulation framework for sepsis and critical illnesses. Nat. Med. 2025;31(12): 4084-4096. doi: 10.1038/s41591-025-03956-5. Go to original source... Go to PubMed...
    2. Wong HR, Cvijanovich NA, Anas N, Allen GL, Thomas NJ, Bigham MT, et al. Developing a clinically feasible personalized medicine approach to pediatric septic shock. Am. J. Respir. Crit. Care Med. 2015;191(3):309-315. doi: 10.1164/rccm.201410-1864OC. Go to original source... Go to PubMed...
    3. Davenport EE, Burnham KL, Radhakrishnan J, Humburg P, Hutton P, Mills TC, et al. Genomic landscape of the individual host response and outcomes in sepsis: a prospective cohort study. Lancet Respir. Med. 2016;4(4):259-271. doi: https://doi.org/10.1016/S2213-2600(16)00046-1. Go to original source... Go to PubMed...
    4. Scicluna BP, van Vught LA, Zwinderman AH, Wiewel MA, Davenport EE, Burnham KL, et al. Classification of patients with sepsis according to blood genomic endotype: a prospective cohort study. Lancet. Respir. Med. 2017;5(10):816-826. doi: 10.1016/S2213-2600(17)30294-1. Go to original source... Go to PubMed...
    5. Sweeney TE, Azad TD, Donato M, Haynes WA, Perumal TM, Henao R, et al. Unsupervised Analysis of Transcriptomics in Bacterial Sepsis Across Multiple Datasets Reveals Three Robust Clusters. Crit. Care Med. 2018;46(6):915-925. doi: 10.1097/CCM.0000000000003084. Go to original source... Go to PubMed...
    6. Yao L, Rey DA, Bulgarelli L, Kast R, Osborn J, Van Ark Emily, et al. Gene Expression Scoring of Immune Activity Levels for Precision Use of Hydrocortisone in Vasodilatory Shock. Shock. 2022;57(3):384-391. doi: 10.1097/SHK.0000000000001910. Go to original source... Go to PubMed...
    7. Kyriazopoulou E, Poulakou G, Milionis H, Metallidis S, Adamis G, Tsiakos K, et al. Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double­‑blind, randomized controlled phase 3 trial. Nat. Med. 2021;27(10):1752-1760. doi: 10.1038/s41591-021-01499-z. Go to original source... Go to PubMed...
    8. Sevransky JE, Rothman RE, Hager DN, Bernard GR, Brown SM, Buchman TG, et al. Effect of Vitamin C, Thiamine, and Hydrocortisone on Ventilator- and Vasopressor­‑Free Days in Patients With Sepsis: The VICTAS Randomized Clinical Trial. JAMA. 2021;325(8):742-750. doi: 10.1001/jama.2020.24505. Go to original source... Go to PubMed...
    9. Gordon AC, Mason AJ, Thirunavukkarasu N, Perkins GD, Cecconi M, Cepkova M, et al. Effect of Early Vasopressin vs Norepinephrine on Kidney Failure in Patients With Septic Shock: The VANISH Randomized Clinical Trial. JAMA. 2016;316(5):509-518. doi: 10.1001/jama.2016.10485. Go to original source... Go to PubMed...

    Return to the content


    Anesteziologie a intenzivní medicína

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.